Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | BRD2 | P25440 | 6/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13904861 | 1.00 | BRD4 (0.43) | BRD4BRD2BRD3CCKBRGPBAR1 | |
| SCHEMBL7546575 | 0.88 | CCKBR (0.53) | BRD4BRD2BRD3CCKBRIDO1 | |
| SCHEMBL6005277 | 0.88 | CCKBR (0.53) | BRD4BRD2BRD3CCKBRIDO1 | |
| SCHEMBL9248094 | 0.88 | CCKBR (0.53) | BRD4BRD2BRD3CCKBRIDO1 | |
| SCHEMBL1574481 | 0.80 | BRD4 (0.62) | BRD4BRD2BRD3CCKBRCCKAR | |
| SCHEMBL1574479 | 0.80 | BRD4 (0.62) | BRD4BRD2BRD3CCKBRCCKAR | |
| SCHEMBL4148160 | 0.80 | SCN9A (0.49) | BRD4BRD2BRD3CCKBRCCKAR | |
| SCHEMBL13904864 | 0.80 | SCN9A (0.49) | BRD4BRD2BRD3CCKBRCCKAR | |
| SCHEMBL4698221 | 0.79 | CCKBR (0.59) | CCKBRCCKARSENP1 | |
| SCHEMBL7550804 | 0.79 | BRD4 (0.45) | BRD4BRD2BRD3CCKBRSENP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-7112583-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | OLSON RICHARD E | 2005-11-24 | — | — | US | disclosed |
| US-6960576-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-6958329-B2 | Lactams substituted by cyclic succinates as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | disclosed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | disclosed |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-06-26 | — | — | US | disclosed |
| US-6509333-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | APP, BACE1, APH1A | BRD4 4052/4885BRD2 3246/4885BRD3 3962/4885 |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | BRD4 3720/4885BRD2 3007/4885BRD3 3789/4885 |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | APP, BACE1, APH1A | BRD4 4216/4885BRD2 4083/4885BRD3 4490/4885 |
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | BACE1, APP, APH1A | BRD4 3825/4885BRD2 3642/4885BRD3 4136/4885 |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | APP, APH1A, APH1B | BRD4 4067/4885BRD2 3628/4885BRD3 4198/4885 |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | APP, APH1A, BACE1 | BRD4 4078/4885BRD2 3497/4885BRD3 4120/4885 |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | APP, BACE1, APH1A | BRD4 3720/4885BRD2 3007/4885BRD3 3789/4885 |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BACE1, APP, APH1A | BRD4 3825/4885BRD2 3642/4885BRD3 4136/4885 |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | BRD4 3720/4885BRD2 3007/4885BRD3 3789/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | BRD4 3102/4885BRD2 1997/4885BRD3 3510/4885 |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | APH1A, APH1B, APP | BRD4 4298/4885BRD2 4067/4885BRD3 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.